希辛可以通过调节NPTX2/C1q/C3补充通路来治疗血管痴呆症
Shuo Yang1, Xin-Qi Gao2, Ai-Hua Tan1
1Department of Central Laboratory, Huang Gang Hospital of Traditional Chinese Medicine of Hubei University of Chinese Medicine, Huanggang, Hubei Province, China.
Chemistry & biodiversity
|December 31, 2024
概括
希的开制剂可以通过调节NPTX2/C1q/C3通路来改善血管痴呆症 (VaD). 这种传统中医治疗有助于恢复认知功能,并减少VaD模型中的神经元损伤.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 血管痴呆 (VaD) 源于脑血管疾病,影响认知功能和日常生活.
- 虽然Xixin蒸对VaD有希望,但其精确的治疗机制在很大程度上仍未被阐明.
- 了解VaD病原和治疗途径对于开发有效的干预措施至关重要.
研究的目的:
- 在血管痴呆症模型中研究Xixin的治疗机制.
- 探索NPTX2/C1q/C3补充通路在VaD中的作用,以及其通过Xixin调节的作用.
主要方法:
- 利用莫里斯水迷宫和新的对象识别测试进行认知评估.
- 使用传输电子显微镜,戈尔吉染色和尼斯尔染色用于神经元形态学.
- 进行了西式涂抹和定量实时PCR来分析蛋白质和基因表达,重点是NPTX2,C1q和C3.3.
主要成果:
- 维多利亚疾病模型组表现出学习障碍,认知缺陷和海马神经元损伤.
- 在VaD模型中观察到NPTX2表达的减少和炎症因子 (C1q,C3) 的增加.
- 施用 Xixin 蒸改善了认知功能,减少了神经元损伤,并调节了 NPTX2 / C1q / C3 途径.
结论:
- 希希辛 (Xixin) 蒸证明了血管痴呆症的治疗潜力.
- 治疗似乎通过调节NPTX2/C1q/C3补充通路来起作用.
- 这些发现提供了对VaD.Xixin的药理机制的洞察力.
相关概念视频
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95


